CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH Orforglipron’s reported side effects were comparable to those of injectable GLP-1 receptor agonists.
New research reveals the potential of orforglipron, a nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist, to significantly reduce body weight in adults with obesity, making it a potential game changer in the battle against this global health concern.
Key Points:
- The Phase 2, double-blind trial involved 272 adults with obesity, or overweight with at least one weight-related coexisting condition, over 36 weeks.
- Participants were randomly assigned orforglipron doses of 12, 24, 36, or 45 mg, or a placebo, to be taken daily.
- Weight reduction of at least 10% by week 36 was achieved by 46 to 75% of participants on orforglipron compared to 9% on placebo.
- Mean body weight reduction ranged from -9.4% to -14.7% with orforglipron at week 36, as compared to -2.3% with placebo.
- The most common adverse events were gastrointestinal, mild to moderate, and resulted in 10 to 17% of participants discontinuing orforglipron use.
Additional Points:
- Adverse events reported with orforglipron were consistent with those experienced with injectable GLP-1 receptor agonists.
- The study reported improvements in all prespecified weight-related and cardiometabolic measures with orforglipron use.
Conclusion:
- The nonpeptide GLP-1 receptor agonist, orforglipron, demonstrated weight reduction efficacy in a clinical trial, with side effects similar to those of injectable GLP-1 receptor agonists.
Internal Medicine Latest Posts
- FDA Clears Cologuard Plus for Colorectal Cancer Screening
- Chlamydial Proctitis
- Commonly Used Arm Positions Can Substantially Overestimate Blood Pressure Readings, Study Finds
- Vitamin D Supplements May Help Improve Blood Pressure, Cholesterol, and Insulin
Did You Know?
As of 2021, more than 650 million adults were obese worldwide, according to the World Health Organization.
